drugset / Trial / NCT04541329
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Phase 4
Completed
7 enrolled
University of California, San Francisco
Sun Pharmaceutical Industries, Inc. · collab
NaSingle-groupOpen-labelBasic science
Summary
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2023-01-15
- Completion
- 2023-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tildrakizumab | Monoclonal antibody | — | — |